William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign To Highlight Critical Importance Of Prompt, Accurate Blood Ammonia Testing For Diagnosing Urea Cycle Disorders
Guggenheim Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $20